CompletedInterventionalPhase 3Updated Aug 10, 2018
Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia | NCT02824380 | Trialant
CompletedInterventionalPhase 1Updated Mar 30, 2018
Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia
ClinicalTrials.gov ID
NCT02824380
Lead Sponsor
Dong-A ST Co., Ltd.INDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 1
Enrollment
14Actual
Last Update Posted
Mar 30, 2018Actual
Start Date
Jul 2016Actual
Primary Completion Date
Oct 2016Actual
Completion Date
Oct 2016Actual
Brief Summary
An Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate the Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects with Androgenic Alopecia.
Androgenic Alopecia
DA-4001 H
DA-4001 L
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
Male
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male, aged between 19 and 65 years, clinically healthy
BMI between 18.5kg/m2 and 27kg/m2
Clinical history of Androgenic Alopecia
Exclusion Criteria:
Subject has any dermatological disorders of the scalp
Subject has a history of hair transplants, hair weaves
Subject has hypersensitivity to previously prescribed minoxidil or finasteride
Subject who is considered inappropriate to participate in the study due to any conditions including screening results at the investigator's discretion